A Behavioural and Histological Approach to Dose Dependent Chronic Toxicity Screening of Cyclotide in Zebrafishes

Parkinson's disease (PD) is the second most common neurodegenerative illness worldwide. It is an age-related sickness. An illness treatment plan is urgently required. Such secondary metabolites from plants may undoubtedly be the source of the medications with less adverse effects. 6-Hydroxydopamine (6-OHDA) is used experimentally to mimic Parkinson's disease in adult zebrafish. In the realm of medicine, there are no ideal cures for ailments. For the past few decades, a number of plant secondary chemicals have been tested in preclinical settings to cure this illness. Many references have been made to cyclotide's neuroprotective, anti-inflammatory, and antioxidant properties. Furthermore, it has recently been demonstrated that amantadine (AMA), an aminoadamantane well-known for its mild antiparkinsonian action, counteracts central nervous system dysfunction. Apart from oxidative stress and mitochondrial damage, 6-OHDA may also cause decreased cytosolic levels of Tyrosine Hydroxylase (TH). Since this is primarily thought to be in charge of dopamine production in the central nervous system, an antagonist of TH may be the best medication option when treating Parkinson's disease. Since Amantadine (AMA) is the conventional medication, the current study compares the potential of Cyclotide as Tyrosine Hydroxylase Inhibitors to examine the molecular anti-TH interactions in 6-OHDA-induced adult zebrafishes.